The company focuses on addressing the unmet medical needs related to dysregulated CoEnzyme A (CoA) metabolism, which plays a crucial role in various cellular processes such as fatty acid and sugar metabolism, gene expression regulation, and mitochondrial health. By leveraging its CoEnzyme Metabolism (CoMET™) Platform, Comet Therapeutics aims to provide therapies for genetic, rare metabolic disorders and diseases like cancer, fatty liver, and neurological disorders. Recently, on August 31st, 2021, Comet Therapeutics was acquired by VectivBio, although the terms of the transaction were not disclosed.